Promising Efficacy and Market Growth Potential Drive Buy Rating for Argenx Se

Analyst Douglas Tsao of H.C. Wainwright reiterated a Buy rating on Argenx Se (ARGX – Research Report), retaining the price target of $720.00.

Douglas Tsao has given his Buy rating due to a combination of factors including the promising long-term efficacy data of Vyvgart in treating generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The data presented at the 2025 American Academy of Neurology Annual Meeting demonstrated significant improvements in patient outcomes, with a substantial percentage achieving minimal symptom expression. This has encouraged physicians to adopt more flexible dosing schedules, enhancing treatment efficacy.
Additionally, the anticipated approval of a prefilled syringe for Vyvgart is expected to facilitate easier self-administration, potentially boosting its market growth. The strong launch of Vyvgart in CIDP, coupled with its unique position as the only approved FcRn therapy for this condition, underscores its competitive advantage. Furthermore, the ongoing development of ARGX-119, with favorable early-phase data, adds to the company’s growth potential. These factors, along with a robust valuation model, support Tsao’s optimistic outlook on Argenx Se’s stock.